Related Experiment Videos
New approaches to the integrated management of early lung cancer
J L Mulshine1, J Zhou, A M Treston
1Biomarkers and Prevention Research Branch, National Cancer Institute, Rockville, Maryland, USA.
Abstract:
We have briefly surveyed some the developments in the field of molecular diagnostics that provide a basis for cautious optimism about progress in population-based early lung cancer screening. The sound lung cancer management strategies that were formulated several decades ago failed in clinical trials because the necessary tools to implement the strategies were not yet available. Technology is beginning to emerge that makes population-based screening achievable. This same technology may be used to define a comprehensive marker panel including the most informative markers from the long list of candidate markers. Validation studies will define more clearly the strengths and limitations of new molecular diagnostics and provide leads for further research attention. The clinical community can expedite this process if these validation efforts are aggressively pursued. Parallel developments are clearly needed in refining the range of therapeutic intervention for early cancer management. The success of both diagnostic and intervention tools is interwoven in the ultimate goal of reducing lung cancer mortality. This article is an invitation to think expansively about new approaches to cancer care that integrate the fruits of our hard-learned lessons.
Insights
Advancements in molecular diagnostics offer hope for effective population-based early lung cancer screening. New technologies and comprehensive marker panels are key to reducing lung cancer mortality.
Area of Science:
- Oncology
- Molecular Diagnostics
- Public Health
Background:
- Historically, lung cancer management strategies lacked the necessary diagnostic tools for effective early detection.
- Past clinical trials for population-based screening failed due to technological limitations.
Purpose of the Study:
- To survey recent developments in molecular diagnostics for early lung cancer screening.
- To highlight the potential of emerging technologies in improving lung cancer management.
- To emphasize the need for validation studies and parallel therapeutic advancements.
Main Methods:
- Review of current advancements in molecular diagnostics.
- Discussion of emerging technologies for population-based screening.
- Exploration of comprehensive marker panel development.
Main Results:
- Emerging technologies are making population-based screening feasible.
- New molecular diagnostics can aid in defining comprehensive marker panels.
- Validation studies are crucial for understanding the strengths and limitations of new diagnostics.
Conclusions:
- Molecular diagnostics provide a basis for optimism in early lung cancer screening.
- Aggressive validation of new diagnostics and refinement of therapies are essential.
- Integrated approaches in diagnostics and intervention are vital for reducing lung cancer mortality.